The Lifecourse Continuum of Human Atherosclerosis

- Synthesizing the fetal, pediatric, and adult pathological record.
- Defining the boundary between arterial adaptation and true disease.
- Evaluating the Apolipoprotein B cumulative-exposure model.
- Based on the research of Peter Megdal, PhD.



We universally treat atherosclerosis as a disease of aging, yet the pathological record proves it begins before birth.

THE MYTH

Prevailing Assumption: A late-life degenerative event.



THE REALITY

Pathological Record: Lipid-retaining lesions present before birth.

If nearly everyone has arterial lesions by later life, in what sense is atherosclerosis a disease at all? Answering this requires mapping the true timeline of the disease and identifying the exact biological boundary where healthy human development crosses into pathology.

The exact histological boundary separating healthy adaptation from cardiovascular disease.

Adaptive Intimal Thickening (Healthy)



- Response to hemodynamic stress at bends/branches
- Smooth muscle cell proliferation
- Zero lipid retention
- Zero inflammation

Intimal Xanthoma (Pathology)



- Apolipoprotein B (apoB) particles retained in matrix
- Oxidative modification
- Inflammatory macrophage infiltration
- Foam cell formation

A pathologist scoring simple thickening as disease will vastly inflate prevalence data. True pathology demands the retention and modification of apoB-containing lipoproteins accompanied by inflammation.

Fetal pathology is driven directly by maternal cholesterol transfer.

The Napoli Autopsy Series (82 Fetal Aortas):

- Fatty streaks containing native and oxidized LDL are demonstrably present in fetal aortas.
- Lesion extent is significantly greater in fetuses of hypercholesterolemic mothers.
- Before six months, fetal plasma cholesterol highly correlates with maternal cholesterol (R = 0.86).
- Crucially, LDL accumulation precedes monocyte recruitment—proving a ‘response-to-retention’ rather than a ‘response-to-injury’ disease origin.

Fetal Stage (6.2 Months) Lifeline

Early pediatric lesions are capable of structural regression once the lipid environment normalizes.



The FELIC Study (156 Normocholesterolemic Children):

- Lesions in the youngest children were smaller than those found in corresponding fetuses.
- This indicates postnatal structural regression occurs once the high-lipid fetal environment resolves.
- However, lesions progressed faster in children of mothers who had hypercholesterolemia, even if the child's own cholesterol was normal.
- Conclusion: The trajectory of an early lesion is not fixed at birth; it is dictated by lifelong exposure.

Fetal Stage (6.2 Months) — Lifeline — Early Childhood (Ages 1–13)

Lesion burden scales with the accumulation of conventional risk factors during adolescence.



PDAY & Bogalusa Autopsy Studies:

- In the PDAY youth stratum (ages 15–19), virtually all aortas and half of right coronary arteries carried visible lesions.
- The extent of these lesions tracks directly with post-mortem markers for non-HDL cholesterol, smoking, adiposity, and glycemia.
- These post-mortem risk scores accurately predict clinical cardiovascular events decades later in living cohorts.

Fetal Stage (6.2 Months) — Lifeline — Adolescence & Young Adulthood (Ages 15–34)

Methodological artifacts explain the seemingly miraculous disappearance of coronary disease in military autopsies.

1953 - Korea (Enos Series)

77.3% Prevalence

Method: Gross visual assessment, unfixed collapsed arteries. Classified fibrous intimal thickening (normal adaptation) as disease.

Modern - Iraq/Afghanistan (Webber Series)



8.5% Prevalence

Method: Standardized 10% formalin fixation, strict Sudan IV staining, independent grading.

While true reductions in smoking and untreated hypertension have lowered disease burden, the drastic drop from 77.3% to 8.5% across six decades is heavily distorted by historical methodologies that mistakenly graded adaptive thickening as atherosclerosis.

By **midlife**, microscopic pathology is nearly universal, but obs**tructive disease** remains a minority outcome.



SCAPIS Cohort (50-64y):
42.1% prevalence of subclinical plaque

SCAPIS Cohort (50-64y):
5.2% significant stenosis

Population imaging confirms extensive subclinical disease:

- PESA (40-54y): 63% have subclinical atherosclerosis in at least one territory.
- SCAPIS (50-64y): 42.1% exhibit coronary atherosclerosis, but only 5.2% possess significant stenosis.
- The Diagnostic Gap: 5.5% of individuals with a perfect coronary calcium score of zero nonetheless have detectable noncalcified plaque.

Apolipoprotein B particles are the necessary initiating substrate for all atherosclerosis.



Every atherogenic lipoprotein particle (LDL, VLDL, IDL, Lp(a)) carries exactly one molecule of apoB.

While measuring LDL-Cholesterol quantifies the mass of cholesterol being transported, measuring apoB quantifies the actual number of particles.

Subendothelial retention is governed by particle flux and electrostatic binding. Therefore, particle number is the mechanistically relevant driver of disease.

Local vascular biology (disturbed flow, endothelial permeability) merely dictates where the retention occurs.

Plaque burden reflects the mathematical integral of exposure over time—the “ApoB-Years” of the heart.

Pack-Years



Lung cancer risk scales with “Pack-Years” (cigarettes per day × years smoked).



Plaque burden scales with “ApoB-Years” (particle concentration × years of exposure).

Atherosclerosis does not happen overnight in old age. It is a function of cumulative retention. Pooled cohort analysis demonstrates that cumulative LDL exposure during young adulthood perfectly predicts midlife cardiovascular events, independent of whatever the patient’s cholesterol happens to be at midlife.

Cumulative exposure in young adulthood predicts later clinical events with a distinct empirical inflection point



The CARDIA Study (4,366 participants tracked from ages 18 to 40):

- Each standard deviation increase in cumulative apoB exposure carried a hazard ratio of 1.53 for incident cardiovascular disease after age 40.
- Risk does not scale perfectly linearly; hazard begins to steeply increase above a usual apoB exposure of **~75 mg/dL per year**.
- Note: The frequently cited figures of “5,000 LDL-years” or “1,500 apoB-years” are mathematical heuristics, not biological constants.

Sustained, early reduction of ApoB fundamencally alters the cardiovascular destiny of high-risk individuals.





20-Year Follow-up of Pediatric Familial Hypercholesterolemia (FH):
Patients with a severe genetic cholesterol disorder (FH) were initiated on statin therapy in childhood. At age 39, their carotid intima-media thickness was indistinguishable from healthy siblings. By dramatically lowering cumulative ApoB-years, early intervention effectively neutralized their genetic disadvantage compared to their untreated affected parents.

Atherosclerosis is an inherent mammalian potential, but its clinical expression is environmentally determined.

The Amazon



The Ancient World



Preindustrial mummies prove the disease is not uniquely modern, likely driven by high infectious burden and particulate smoke. However, the Tsimane prove that humans can reach advanced age with virtually zero coronary calcification if lifetime ApoB exposure is kept low.

Dietary modification safely lowers lifetime ApoB exposure, even beginning in childhood.

Dietary Portfolio

Plant sterols, viscous fiber, tree nuts. Achieves LDL reduction nearing first-generation statins.

PREDIMED

The Mediterranean pattern. Reduces events through whole-food lipid modulation, proving benefit does not strictly require fat elimination.

DISC & STRIP Trials

Reduced-fat, cholesterol-lowering diets initiated in children (aged 7 months to 10 years).

The principal objection to pediatric lipid-lowering diets is the fear of impairing growth or neurodevelopment. Rigorous randomized trials (DISC and STRIP) confirm that early dietary counseling and fat optimization produce significant cholesterol reduction with absolutely zero adverse effects on height, iron status, sexual maturation, or neurodevelopment.

The Polyunsaturated Fat Debate: Differentiating transient postprandial signals from long-term cardiovascular outcomes.

Long-Term Outcomes

- Cochrane review (56,000+ participants) shows 17% reduction in events when substituting polyunsaturated fat for saturated fat.
- AHA confirms ~30% reduction.



The Transient Signal

- High-fat meals transiently impair flow-mediated dilation for ~6 hours (also true of olive oil).
- Historical trial re-analyses (Sydney/Minnesota) show higher mortality, but suffer from extreme methodological flaws and trans-fat confounding.

The apoB-lowering mechanism of polyunsaturated fats is supported by human genetics and randomized outcome trials. Recommendations treating vegetable oils as a primary vascular hazard are not supported by the aggregate data.

Statistical ubiquity in aging Western populations is not evidence of physiological normality.



The claim that “everyone has atherosclerosis” is frequently used to argue that the disease is a normal consequence of aging. This conflates microscopic lipid retention with plaque rupture.

Hypertension and insulin resistance are also statistically ubiquitous in aging Western populations, yet we do not accept them as healthy reference states.

Atherosclerosis is a biological potential, but clinical heart disease is a highly modifiable destiny.



Given sufficient apoB exposure and time, the human intima will retain lipid. In this limited sense, microscopic plaque development is an inherent capacity of the human artery. However, the rate of progression is never fixed. Because the disease is a strict mathematical function of cumulative apoB exposure—and because that exposure is highly modifiable through diet and pharmacology—the near-universality of late-life atherosclerosis is a mandate for early, sustained intervention, not therapeutic fatalism.

Visual assisted by AI. Reviewed by Peter Megdal, PhD.